- Trials with a EudraCT protocol (157)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
157 result(s) found for: Overweight.
Displaying page 1 of 8.
EudraCT Number: 2008-001049-24 | Sponsor Protocol Number: NN8022-1839 | Start Date*: 2008-12-02 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multina... | ||||||||||||||||||
Medical condition: Obesity and overweight Pre-diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) AT (Completed) GB (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003380-35 | Sponsor Protocol Number: EX9536-4388 | Start Date*: 2018-10-05 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity | ||||||||||||||||||
Medical condition: Overweight Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) DK (Completed) FI (Completed) IE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) LV (Completed) NL (Completed) CZ (Completed) HU (Completed) BE (Completed) AT (Completed) SE (Completed) HR (Completed) NO (Completed) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006352-36 | Sponsor Protocol Number: VPN-10-18 | Start Date*: 2013-04-11 | ||||||||||||||||
Sponsor Name:Lithuanian University of Health Sciences, Endocrinology Department | ||||||||||||||||||
Full Title: Obesity in children and adolescents: complications, associated risks and early intervention (lifestyle changes and insulin sensitivity improving medicine (metformin) effectiveness and safety evalua... | ||||||||||||||||||
Medical condition: The aim of our study is to establish the effectivenes and safety of metformin use in pediatric obese population; to assess the prevalence of insulin resistance, metabolic syndrome, polycystic ovary... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: LT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004919-11 | Sponsor Protocol Number: FLAIR-i | Start Date*: 2022-05-03 | ||||||||||||||||
Sponsor Name:Donders Institute for Brain, Cognition and Behaviour, Radboud University | ||||||||||||||||||
Full Title: The effect of colchicine on Food-reLAted effort-based decision making in brain and behavIouR in overweight and obesity: the FLAIR-i study. | ||||||||||||||||||
Medical condition: Low-grade inflammation in obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002953-11 | Sponsor Protocol Number: NN9932-4737 | Start Date*: 2021-06-23 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity | ||||||||||||||||||
Medical condition: Obesity Overweight | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000775-42 | Sponsor Protocol Number: RIMON_L_00075 | Start Date*: 2007-12-27 | |||||||||||
Sponsor Name:University Hospital Tübingen | |||||||||||||
Full Title: Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial | |||||||||||||
Medical condition: overweight, obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002199-88 | Sponsor Protocol Number: NN8022-1922 | Start Date*: 2008-12-15 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multina... | ||||||||||||||||||
Medical condition: Obesity and overweight | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003726-32 | Sponsor Protocol Number: NN9536-4378 | Start Date*: 2018-08-22 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Two-year effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity | ||||||||||||||||||
Medical condition: Obesity Overweight | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) ES (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002470-86 | Sponsor Protocol Number: 20190218 | Start Date*: 2023-05-08 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without... | ||||||||||||||||||
Medical condition: Overweight and Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) CZ (Ongoing) ES (Ongoing) PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003062-13 | Sponsor Protocol Number: AZP01-CLI-003 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Millendo Therapeutics SAS | |||||||||||||
Full Title: A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome | |||||||||||||
Medical condition: Prader-Willi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002868-14 | Sponsor Protocol Number: CLIK066B2201 | Start Date*: 2017-04-18 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 wee... | ||||||||||||||||||
Medical condition: change in weight in obese or overweight adults | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) CZ (Completed) AT (Completed) HU (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002431-18 | Sponsor Protocol Number: NN9536-4451 | Start Date*: 2019-09-25 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity | ||||||||||||||||||
Medical condition: Overweight Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) IE (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000882-41 | Sponsor Protocol Number: NN9535-4984 | Start Date*: 2022-07-27 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Investigation of once-weekly semaglutide s.c. dose-response in patients with type 2 diabetes and overweight – a participant- and investigator-blinded and sponsor open-label study | ||||||||||||||||||
Medical condition: Diabetes Mellitus, Type 2 Overweight | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) GR (Completed) PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000907-13 | Sponsor Protocol Number: 2007-24-001 | Start Date*: 2007-11-13 | ||||||||||||||||||||||||||
Sponsor Name:MUW, Innere Med III, Abt.für Endokrinologie & Stoffwechsel | ||||||||||||||||||||||||||||
Full Title: The impact of Rimonabant in overweight women with prior gestational diabetes | ||||||||||||||||||||||||||||
Medical condition: Rimonabant has been shown to reduce body weight and improve cardiovascular risk factors and metabolic control. Therefore we investigate in women with previous gestational diabetes and impaired glu... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000223-85 | Sponsor Protocol Number: 140631 | Start Date*: 2015-04-09 |
Sponsor Name:Örebro University Hospital | ||
Full Title: The effects of Vitamin D supplementation on cardiorespiratory fitness and adiposity in overweight men. A randomised, double-blind, placebo controlled study. | ||
Medical condition: We aim to examine the effects of Vitamin D supplementation on cardiorespiratory fitness and adiposity in overweight men. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003637-26 | Sponsor Protocol Number: D5881C00007 | Start Date*: 2015-02-27 |
Sponsor Name:AstraZenenca AB | ||
Full Title: A double-blind randomized placebo-controlled, parallel-group 12 week study to investigate the effects of Epanova® compared to placebo and compared to Fenofibrate on liver Fat content in hypertrig... | ||
Medical condition: Patients with overweight and high serum triglyceride levels who have Non-alcoholic fatty liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001945-14 | Sponsor Protocol Number: NN9838-4433 | Start Date*: 2019-01-10 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Investigation of safety and efficacy of NNC0174-0833 for weight management – a dose finding trial | ||||||||||||||||||
Medical condition: Obesity Overweight | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) DK (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000324-34 | Sponsor Protocol Number: APD356-G000-401 | Start Date*: 2014-09-10 | ||||||||||||||||
Sponsor Name:Eisai Limited | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long-Term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Even... | ||||||||||||||||||
Medical condition: Obese and overweight patients with cardiovascular (CV) disease and/or multiple CV risk factors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000439-10 | Sponsor Protocol Number: UOE/01-2011 | Start Date*: 2011-07-11 | |||||||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||||||||||||
Full Title: Effect of metformin and clomiphene in obese hypogonadal men with or without type 2 diabetes on plasma levels of testosterone and metabolic parameters | |||||||||||||||||||||||
Medical condition: obese subjects with type 2 diabetes and hypogonadism | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004251-21 | Sponsor Protocol Number: HM-EXC-205 | Start Date*: 2014-03-31 | |||||||||||
Sponsor Name:Hanmi Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: A 20-week, double blind, randomized, placebo controlled, parallel group trial to assess the safety and efficacy of HM11260C on body weight in obese subjects without diabetes. | |||||||||||||
Medical condition: Weight reduction | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
![](img/rss.png)
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
![](img/info.png)